Nilvadipine is a dihydropyridine calcium channel blocker used for the treatment of hypertension and chronic major cerebral artery occlusion. Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be + some more technical info; preclinical data indicate nilvadipine can reduce infarct size and preserve penumbral neuronal viability through vasodilatory effects on cerebral microvasculature, attenuation of microglial activation, and reduction of oxidative stress markers. Chemically, nilvadipine is a lipophilic molecule that readily crosses the blood brain barrier, with oral absorption followed by significant first pass hepatic metabolism predominantly via cytochrome P450 pathways, a plasma half life in the range commonly reported for dihydropyridines, and a pharmacodynamic profile characterized by arterial vasodilation and reduction in peripheral vascular resistance.
Typical quality specifications for nilvadipine reference ICH Q3 guidelines and define related substances as process- and degradation-derived compounds such as de-esterified products, dealkylated analogues, nitro group reduction products, and positional isomers; analytical control is commonly achieved by validated HPLC with a reporting threshold informed by ICH and product daily dose. As guidance ranges used in regulatory dossiers and monographs, individual specified related substances are typically limited to not more than 0.2 to 0.5 percent by area, the reporting threshold for unidentified impurities is commonly set at 0.05 to 0.10 percent, and total impurities are often controlled to not exceed about 1.0 to 2.0 percent, with tighter limits applied to genotoxic or otherwise hazardous degradants and with routine tests for assay, residual solvents, and heavy metals included in the specification.
Nilvadipine is used primarily to treat hypertension and to improve cerebral blood flow in conditions involving major cerebral artery occlusion; its clinical use is based on its arterial vasodilatory action to lower blood pressure and its ability to increase regional cerebral perfusion.
Nilvadipine blocks L-type calcium channels in vascular smooth muscle, leading to arterial vasodilation, decreased systemic vascular resistance, and increased cerebral blood flow; these effects account for its antihypertensive action and potential neuroprotective effects observed in experimental models.
Purity and related substances are typically assessed by validated high performance liquid chromatography methods with UV detection, supported by mass spectrometry for structural identification of impurities, along with complementary tests for residual solvents by GC and elemental impurities by ICP.
Nilvadipine is photosensitive and should be stored protected from light in a cool, dry environment; stability studies inform shelf life and identify potential degradation pathways such as hydrolysis or reduction of the nitro moiety, which are controlled through formulation, packaging, and appropriate storage conditions.
